Relay Therapeutics' Zovegalisib Shows 60% Response Rate in Vascular Anomalies Trial
Event summary
- Relay Therapeutics reported initial Phase 2 trial data for zovegalisib, showing a 60% volumetric response rate in patients with PIK3CA-driven vascular anomalies.
- 89% of patients showed clinical improvement at week 12, with no treatment discontinuations due to adverse events.
- Expansion cohorts for adults and adolescents are now open at 400mg once daily and 300mg twice daily.
- The trial includes 32 patients, with 20 evaluated for efficacy as of the April 15, 2026 data cut-off.
The big picture
Relay Therapeutics' zovegalisib is designed to address a significant unmet need in PIK3CA-driven vascular anomalies, a rare disease area with limited treatment options. The promising initial data positions zovegalisib as a potential differentiated therapy, leveraging its mutant-selective inhibition profile. The company is also advancing zovegalisib in metastatic breast cancer, highlighting its dual-market strategy in precision medicine.
What we're watching
- Clinical Efficacy
- How the 60% volumetric response rate and 89% clinical improvement will position zovegalisib against existing treatments for vascular anomalies.
- Safety Profile
- Whether the favorable safety profile observed in the Phase 2 trial will translate to long-term chronic use in patients.
- Regulatory Pathway
- The pace at which Relay Therapeutics can advance zovegalisib through subsequent trial phases and potential regulatory approvals.
Related topics